nccn guidelines update: impact of ipilimumab and nivolumab as preferred regimen for ccrcc
Published 1 month ago • 144 plays • Length 15:10Download video MP4
Download video MP3
Similar videos
-
0:39
dr. lopes on the fda approval of nivolumab/ipilimumab in nsclc
-
8:07
hcrn gu16-260: nivolumab, salvage nivo/ipi in advanced clear cell rcc
-
2:13
nivolumab in hnscc
-
1:09
nccn clinical practice guidelines in oncology (nccn guidelines®) for survivorship
-
8:08
pancreatic cancer: updated nccn guidelines
-
6:03
checkmate 9la: nivolumab, ipilimumab and chemotherapy for stage iv nsclc
-
1:54
the ideal patient population for the use of nivolumab in treatment of nsclc
-
6:01
metastatic rcc: using frontline ipilimumab/nivolumab
-
2:31
toni choueiri, md, describes treatment strategies for 2nd line renal cell carcinoma
-
1:44:11
challenging cases in precision medicine and immuno-oncology 2020-10-12
-
1:45
immuno-oncology in renal cell carcinoma: new combinations are coming
-
1:00:20
it’s precisely the time for more precision in genomic testing and targeted treatment of nsclc
-
44:08
recent advances in the diagnosis & classification of renal cell carcinomas
-
5:12
renal cell carcinoma trial analysis: current landscape of immunotherapy combinations
-
6:36
frontline clinical trials in renal cell carcinoma
-
5:43
renal cell carcinoma progression
-
8:50
comparison of frontline renal cell carcinoma treatment options
-
2:00
nivolumab and ipilimumab in mrcc